Patients with relapsing MS treated with tolebrutinib vs teriflunomide had a clear reduction in disability accumulation with no difference in relapses.
Maria Lowe, Pharm.D., BCPS, associate vice president of pharmaceutical intelligence at the Institute for Clinical and ...
Zacks Investment Research on MSN1d
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS StudySwiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus ...
Clinical Trials Arena on MSN1d
Roche’s high-dose Ocrevus fails primary endpoint in MS trialHigher doses of the company’s intravenously delivered multiple sclerosis drug failed to show additional benefit in slowing ...
Columnist Ahna Crum spent years trying to go it alone. Now she knows that freedom comes when she's flocking together with ...
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing ...
A decision on tolebrutinib for treating MS is now set for Sept. 28, after the FDA granted priority review to its approval ...
Sanofi’s tolebrutinib has been accepted for priority review by the US Food and Drug Administration (FDA) to treat certain ...
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability ...
US FDA accepts for priority review Sanofi’s regulatory submission of tolebrutinib for patients with multiple sclerosis: Paris Wednesday, March 26, 2025, 09:00 Hrs [IST] The US F ...
The U.S. Food and Drug Administration is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing ...
FDA grants Priority Review status to Sanofi's tolebrutinib for the treatment of non-relapsing secondary progressive multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback